Data from the global Transthyretin Amyloidosis Outcome Survey (THAOS) registry demonstrated that up to one-third of asymptomatic transthyretin gene carriers (36.2% Val30Met, 34.6% non-Val30Met) develop amyloid disease within a median of 2.2 years [37]. This evidence concerns the gene TTR and amyloidosis.